Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegpleranib + aflibercept
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravitreal
01
Overview
Pegpleranib + aflibercept is a combination therapy investigated for the treatment of neovascular age-related macular degeneration (nAMD). Pegpleranib is an aptamer that selectively binds to platelet-derived growth factor-BB (PDGF-BB), preventing it from interacting with its receptor PDGFR-β, thereby disrupting pericyte support of abnormal blood vessels and promoting regression of neovascular lesions. Aflibercept is a recombinant fusion protein that acts as a decoy receptor for vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF), thereby inhibiting pathological angiogenesis and vascular permeability. The combination is designed to target both VEGF-driven and PDGF-driven pathways involved in abnormal blood vessel growth in the retina[1][3][5].
- Other names
- pegpleranib + afliberceptFovista + Eylea
02
Targets
Beyond the preview
Go deeper on pegpleranib + aflibercept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegpleranib + aflibercept.